|
1.
|
Adjei AA, Marks RS and Bonner JA: Current
guidelines for the management of small cell lung cancer. Mayo Clin
Proc. 74:809–816. 1999. View
Article : Google Scholar : PubMed/NCBI
|
|
2.
|
Simon GR and Wagner H: For the American
College of Chest Physicians. Small cell lung cancer. Chest.
123(Suppl): 259S–271S. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
3.
|
National Comprehensive Cancer Network:
National Comprehensive Cancer Network practice guidelines in
oncology v. 1.2007: small cell lung cancer. Available at:
http://www.nccn.org/professionals/physician_gls/PDF/sclc.pdfuri.
Accessed January 9, 2007.
|
|
4.
|
Hyde L, Yee J, Wilson R and Panto ME: Cell
type and the natural history of lung cancer. JAMA. 193:52–54. 1965.
View Article : Google Scholar : PubMed/NCBI
|
|
5.
|
Lassen U, Osterlind K, Hansen M,
Dombernowsky P, Bergman B and Hansen HH: Long term survival in
small-cell lung cancer: posttreatment characteristics in patients
surviving 5 to 18+ years – an analysis of 1,714 consecutive
patients. J Clin Oncol. 13:1215–1220. 1995.PubMed/NCBI
|
|
6.
|
Rawson NS and Peto J: An overview of
prognostic factors in small cell lung cancer. A report from the
Subcommittee for the Management of Lung Cancer of the United
Kingdom Coordinating Committee on Cancer Research. Br J Cancer.
61:597–604. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
7.
|
Knez L, Sodja E, Kern I, Košnik M and
Cufer T: Predictive value of multidrug resistance protein,
topoisomerases II and ERCC1 in small cell lung cancer: A systematic
review. Lung Cancer. 72:271–279. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8.
|
Kin YH, Ishii G, Goto K, Ota S, Kubota K,
Murata Y, Mishima M, Saijo N, Nishiwaki Y and Ochiai A: Expression
of the breast cancer resistance protein is associated with a poor
clinical outcome in patients with small-cell lung cancer. Lung
Cancer. 65:105–111. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9.
|
Bartel DP: MicroRNAs: genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
10.
|
Ambros V: The functions of animal
microRNAs. Nature. 431:350–355. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
11.
|
Lewis BP, Burge CB and Bartel DP:
Conserved seed pairing, often flanked by adenosines, indicated that
thousands of human genes are microRNA targets. Cell. 120:15–20.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Zeng Y, Yi R and Cullen BR: MicroRNAs and
small interfering RNAs can inhibit mRNA expression by similar
mechanisms. Proc Natl Acad Sci USA. 100:9779–9784. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
13.
|
Zeng Y, Wagner EJ and Cullen BR: Both
natural and designed microRNAs can inhibit the expression of
cognate mRNAs when expressed in human cells. Mol Cell. 9:1327–1333.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Chin LJ, Ratner E, Leng S, et al: A SNP in
a let-7 microRNA complementary site in the KRAS 3′ untranslated
region increases non-small cell lung cancer risk. Cancer Res.
68:8535–8540. 2008.PubMed/NCBI
|
|
15.
|
Brendle A, Lei H, Brandt A, Johansson R,
Enquist K, Henriksson R, Hemminki K, Lenner P and Försti A:
Polymorphisms in predicted microRNA-binding sites in integrin genes
and breast cancer: ITGB4 as prognostic marker. Carcinogenesis.
29:1394–1399. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16.
|
Yu Z, Li Z, Jolicoeur N, Zhang L, Fortin
Y, Wang E, Wu M and Shen SH: Aberrant allele frequencies of the
SNPs located in microRNA target sites are potentially associated
with human cancers. Nucleic Acids Res. 35:4535–4541. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
17.
|
Landi D, Gemignani F, Naccarati A, Pardini
B, Vodicka P, Vodickova L, Novotny J, Forsti A, Hemminki K, Canzian
F and Landi S: Polymorphisms within microRNA-binding sites and risk
of sporadic colorectal cancer. Carcinogenesis. 29:579–584. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
18.
|
Saunders MA, Liang H and Li W-H: Human
polymorphism at microRNA and microRNA target sites. Proc Natl Acad
Sci USA. 9:3300–3305. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
19.
|
Gao Y, He Y, Ding J, et al: An
insertion/deletion polymorphism at miRNA-122-binding site in the
interleukin-1alpha 3′ untranslated region confers risk for
hepatocellular carcinoma. Carcinogenesis. 30:2064–2069.
2009.PubMed/NCBI
|
|
20.
|
Fang J, Feng Q, Ketel CS, Wang H, Cao R,
Xia L, Erdjument-Bromage H, Tempst P, Simon JA and Zhang Y:
Purification and functional characterization of SET8, a nucleosomal
histone H4-lysine 20-specific methyltransferase. Curr Biol.
12:1086–1099. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
21.
|
Nishioka K, Rice JC, Sarma K,
Erdjument-Bromage H, Werner J, Wang Y, Chuikov S, Valenzuela P,
Tempst P, Steward R, Lis JT, Allis CD and Reinberg D: PR-Set7 is a
nucleosome-specific methyltransferase that modifies lysine 20 of
histone H4 and is associated with silent chromatin. Mol Cell.
9:1201–1213. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
22.
|
Wu S, Wang W, Kong X, Congdon LM, Yokomori
K, Kirschner MW and Rice JC: Dynamic regulation of the PR-Set7
histone methyltransferase is required for normal cell cycle
progression. Genes Dev. 24:2531–2542. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23.
|
Song F, Zheng H, Liu B, Wei S, Dai H,
Zhang L, Calin GA, Hao X, Wei Q, Zhang W and Chen K: An
miR-502-binding site single-nucleotide polymorphism in the
3′-untranslated region of the SET8 gene is associated with early
age of breast cancer onset. Clin Cancer Res. 19:6292–6300.
2009.
|
|
24.
|
Guo Z, Wu C, Wang X, Wang C, Zhang R and
Shan B: A polymorphism at the miR-502 binding site in the
3’-untranslated region of the histone methyltransferase SET8 is
associated with hepatocellular carcinoma outcome. Int J Cancer. Nov
18–2011. View Article : Google Scholar : (E-pub ahead of
print).
|
|
25.
|
Shi X, Kachirskaia I, Yamaguchi H, West
LE, Wen H, Wang EW, Dutta S, Appella E and Gozani O: Modulation of
p53 function by SET8-mediated methylation at lysine 382. Mol Cell.
27:636–46. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
26.
|
Merritt WM, Lin YG, Han LY, et al: Dicer,
Drosha, and outcomes in patients with ovarian cancer. N Engl J Med.
359:2641–2650. 2008. View Article : Google Scholar : PubMed/NCBI
|
